89Bio company information, Employees & Contact Information

89bio to Participate in Upcoming Investor Conferences Yahoo Finance

89bio to be Acquired by Roche for Up to $20.50 per Share, Totaling $3.5 Billion in Transaction Value Quiver Quantitative

Roche commences tender offer for all shares of 89bio, Inc. GlobeNewswire

Biotech 89bio Grants 64,750 Stock Options to New Hires with 4-Year Vesting Schedule Stock Titan

$3.5 Billion Biotech Deal: Roche Acquires 89bio for Breakthrough MASH Treatment Pegozafermin Stock Titan

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance

Roche to acquire liver drug developer 89bio for up to $3.5 billion Reuters

After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks Fierce Biotech

89bio, Inc. Prices Upsized Public Offering of Common Stock and Pre-funded Warrants Expected to Raise Approximately $250 Million Quiver Quantitative

$20.50 Per Share Deal: Roche Makes Move to Acquire 89bio in Major Biotech Tender Offer Stock Titan

Roche to buy 89bio in deal worth up to $3.5B, picking up MASH drug statnews.com

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH? Endpoints News

89bio Awards Major Stock Options Package: 267,000 Shares to 3 New Hires in Liver Disease Research Push Stock Titan

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH Yahoo Finance

$3.5B Potential Deal: Roche Acquires 89bio's Breakthrough MASH Treatment in Major Metabolic Disease Push Stock Titan

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline Yahoo Finance

Liver Disease Biotech 89bio Lines Up Triple Conference Presence: Citi, Cantor, and H.C. Wainwright Stock Titan

Roche dives into MASH with $2.4B deal for 89bio BioPharma Dive

Roche Makes Major MASH Move With $3.5B 89bio Buy BioSpace

Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug Fierce Biotech

Roche to Buy Biopharmceutical Firm 89bio in $3.5 Billion Deal Bloomberg.com

How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio BioSpace

89bio: Pegozafermin MASH Drug Advancement Nets Roche Acquisition (NASDAQ:ETNB) Seeking Alpha

Pegozafermin improves fibrosis, shows promise as ‘mainstay treatment’ for NASH Healio

Roche Expands Cardiometabolic Pipeline With 89bio Acquisition (OTCMKTS:RHHBY) Seeking Alpha

89bio: Promising As Pegozafermin Nears Phase 3 Readout (NASDAQ:ETNB) Seeking Alpha

Roche acquires 89bio for US$3.5bn European Biotechnology Magazine

Roche punts up to $3.5B to acquire 89bio The Pharma Letter

89bio: A Buy With Strong Market Opportunity In MASH And SHTG Seeking Alpha

Switzerland’s Roche strikes $3.5bn deal to buy US drugmaker 89bio Financial Times

Why 89bio Stock Lagged the Market Today The Motley Fool

Roche deal to buy 89bio boosts MASH space (ETNB:NASDAQ) Seeking Alpha

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push Benzinga

Pegozafermin Shows Sustained Benefit for NASH in Phase 2b Extension Study HCPLive

89bio’s Pegozafermin Is Now Gaining Momentum (NASDAQ:ETNB) Seeking Alpha

Pegozafermin Enters Phase 3 Clinical Trial Program for MASH, Fibrosis HCPLive

MASH dash speeds up as Roche acquires 89bio for up to $3.5B BioWorld MedTech

89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious Stocktwits

89bio (ETNB) Q2 R&D Jumps 131% The Motley Fool

89bio lines up China CDMO to build API plant for commercial production of MASH candidate Fierce Pharma

Pegazofermin Enters Phase 3 ENLIGHTEN Clinical Trial Program for MASH Patient Care Online

89bio, Inc. Announces Upsized Pricing of $94.5 GlobeNewswire

ENLIVEN: Pegozafermin Could Reduce, Improve Fibrosis in NASH HCPLive

89bio Announces Closing of its Upsized $94.5 Million Public GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) By Investing.com Investing.com South Africa

89bio Appoints Hank Mansbach, M.D., as Chief Medical Officer PR Newswire

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire

ETNB Stock Price and Chart — NASDAQ:ETNB TradingView